These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 35840720)
1. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. Baxi V; Lee G; Duan C; Pandya D; Cohen DN; Edwards R; Chang H; Li J; Elliott H; Pokkalla H; Glass B; Agrawal N; Lahiri A; Wang D; Khosla A; Wapinski I; Beck A; Montalto M Mod Pathol; 2022 Nov; 35(11):1529-1539. PubMed ID: 35840720 [TBL] [Abstract][Full Text] [Related]
2. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments. Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364 [TBL] [Abstract][Full Text] [Related]
3. An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability. Lee KS; Choi E; Cho SI; Park S; Ryu J; Puche AV; Ma M; Park J; Jung W; Ro J; Kim S; Park G; Song S; Ock CY; Choe G; Park JH Histopathology; 2024 Jul; 85(1):81-91. PubMed ID: 38477366 [TBL] [Abstract][Full Text] [Related]
4. Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma. Santos-Briz A; Cañueto J; Carmen SD; Barrios B; Yuste M; Bellido L; Ludeña MD; Román C Am J Dermatopathol; 2021 Jun; 43(6):423-428. PubMed ID: 33395045 [TBL] [Abstract][Full Text] [Related]
5. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372 [TBL] [Abstract][Full Text] [Related]
6. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Udall M; Rizzo M; Kenny J; Doherty J; Dahm S; Robbins P; Faulkner E Diagn Pathol; 2018 Feb; 13(1):12. PubMed ID: 29426340 [TBL] [Abstract][Full Text] [Related]
7. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201 [TBL] [Abstract][Full Text] [Related]
8. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602 [TBL] [Abstract][Full Text] [Related]
9. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma. Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834 [TBL] [Abstract][Full Text] [Related]
10. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161 [TBL] [Abstract][Full Text] [Related]
11. A new AI-assisted scoring system for PD-L1 expression in NSCLC. Huang Z; Chen L; Lv L; Fu CC; Jin Y; Zheng Q; Wang B; Ye Q; Fang Q; Li Y Comput Methods Programs Biomed; 2022 Jun; 221():106829. PubMed ID: 35660765 [TBL] [Abstract][Full Text] [Related]
12. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779 [TBL] [Abstract][Full Text] [Related]
13. A Pipeline for Evaluation of Machine Learning/Artificial Intelligence Models to Quantify Programmed Death Ligand 1 Immunohistochemistry. Knudsen BS; Jadhav A; Perry LJ; Thagaard J; Deftereos G; Ying J; Brintz BJ; Zhang W Lab Invest; 2024 Jun; 104(6):102070. PubMed ID: 38677590 [TBL] [Abstract][Full Text] [Related]
14. Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score. Galsky MD; Bajorin DF; Witjes JA; Gschwend JE; Tomita Y; Nasroulah F; Li J; Collette S; Valderrama BP; Grimm MO; Appleman L; Gravis G; Necchi A; Ye D; Stenner F; Wind-Rotolo M; Zhang J; Ünsal-Kaçmaz K Eur Urol; 2023 May; 83(5):432-440. PubMed ID: 36868932 [TBL] [Abstract][Full Text] [Related]
15. Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma. Phillips T; Millett MM; Zhang X; Jansson M; Cleveland R; Simmons P; Cherryholmes G; Carnahan J; William J; Spaulding B; Satnick IR; Inzunza HD; Taylor C; Cogswell J; Novotny J; Oroudjev E; Winther H Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):6-12. PubMed ID: 29189265 [TBL] [Abstract][Full Text] [Related]
16. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845 [TBL] [Abstract][Full Text] [Related]
17. Development of an automated combined positive score prediction pipeline using artificial intelligence on multiplexed immunofluorescence images. Vahadane A; Sharma S; Mandal D; Dabbeeru M; Jakthong J; Garcia-Guzman M; Majumdar S; Lee CW Comput Biol Med; 2023 Jan; 152():106337. PubMed ID: 36502695 [TBL] [Abstract][Full Text] [Related]
18. Assessment of PD-L1 expression and tumour infiltrating lymphocytes in early-stage non-small cell lung carcinoma with artificial intelligence algorithms. Molero A; Hernandez S; Alonso M; Peressini M; Curto D; Lopez-Rios F; Conde E J Clin Pathol; 2024 Oct; ():. PubMed ID: 39419594 [TBL] [Abstract][Full Text] [Related]
19. Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. Zajac M; Boothman AM; Ben Y; Gupta A; Jin X; Mistry A; Sabalos C; Nielsen A; Manriquez G; Barker C; Antal J; Wang P; Patil P; Schechter N; Rebelatto MC; Walker J Arch Pathol Lab Med; 2019 Jun; 143(6):722-731. PubMed ID: 30457897 [TBL] [Abstract][Full Text] [Related]
20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]